CAR T-Cell Therapy at Acıbadem in Türkiye: A Guide for International Patients

CAR T-cell therapy may be considered for selected patients with certain blood cancers that have returned or have not responded adequately to previous treatment. It is a complex, highly individualized cellular therapy—not a general treatment for every leukemia or lymphoma diagnosis.

For international patients, the first step is a specialist review of the confirmed diagnosis, disease status, prior treatments, overall health and available alternatives. This guide explains the treatment pathway and how MedTransplant can help prepare a case for hospital evaluation in Türkiye without promising eligibility, acceptance, timing, price or outcome.

What Is CAR T-Cell Therapy?

CAR T-cell therapy is a form of cellular immunotherapy. T cells—immune cells collected from blood—are genetically modified in a specialized laboratory so that they express a chimeric antigen receptor, or CAR. This receptor is designed to recognize a selected antigen on certain cancer cells.

After the modified cells are prepared and returned by infusion, they can identify cells carrying that target and activate an immune response. The National Cancer Institute explains that this is a living-cell treatment whose use, benefits and risks depend on the specific disease, target, product and patient.

How Does CAR T-Cell Therapy Work?

The supplied Acıbadem material presents a sequence beginning with blood collection and cell separation, followed by laboratory modification and preparation, infusion and target recognition. Actual clinical pathways can include additional evaluation, disease-control treatment, conditioning chemotherapy, quality checks and close monitoring.

• Blood is collected and white blood cells containing T cells are separated.
• The remaining blood components are returned during the collection process.
• T cells are genetically modified to express a receptor aimed at a defined cancer-cell antigen.
• The modified cells are expanded, prepared and quality checked.
• The CAR T cells are infused according to the specialist treatment plan.
• The cells can recognize the selected target, while the clinical team monitors response and complications.

Which Conditions May Be Considered?

The supplied Acıbadem flyer specifically identifies B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL) for its described program. It does not establish that every subtype, disease stage or patient within these broad diagnoses is eligible.

Eligibility may depend on the exact pathology and antigen target, whether disease is relapsed or refractory, previous therapies and response, current disease burden, organ function, infection status, clinical stability and access to an appropriate product. Final indications and current availability must be confirmed directly by the treating specialists.

CAR T-Cell Production

CAR T-cell products may be commercially manufactured or produced within selected academic or clinical programs. In either route, manufacturing is specialized and involves cell handling, genetic modification, expansion and quality controls before a product can be considered for infusion.

The supplied Acıbadem flyer states that Acıbadem produces patient-specific CAR T cells and reports a minimum production period of 14 days. A separate Acıbadem page updated in April 2026 describes approximately 21 days for production and quality control. These figures belong to different published Acıbadem materials and must not be treated as a guaranteed treatment timetable. Product pathway, quality testing, the patient’s condition and clinical planning can change the schedule.

CAR T-Cell Therapy at Acıbadem

According to information provided by Acıbadem, its hematology and bone marrow transplantation units serve adult and pediatric international patients, and CAR T-cell therapy is among the advanced cancer-treatment options it describes. The hospital must confirm the appropriate campus, team, product and pathway for each case.

The supplied flyer reports that Acıbadem-developed CAR T-cell products had been used in 24 patients at the time represented by that document, primarily for lymphoma and leukemia. It also describes Acıbadem as the first and only CAR T-cell producer in Türkiye and nearby regions. These are historical, source-specific institutional claims; MedTransplant has not independently verified them as current 2026 facts, and the figure is not a success rate.

Acıbadem is a featured partner review route, not a patient’s only option. MedTransplant can help request comparison with other suitable verified programs where appropriate.

International Patient Evaluation

Submitting a case begins an evaluation; it does not establish eligibility or acceptance. Treating hematology and cellular-therapy specialists decide whether CAR T-cell therapy, another treatment or further investigation is appropriate. MedTransplant organizes navigation and referral but does not diagnose disease or determine CAR T-cell eligibility.

Patients should not delay urgent or ongoing care while considering travel. Rapidly changing symptoms, infection, bleeding, breathing difficulty, neurological symptoms or other urgent concerns require assessment through local medical and emergency services.

Medical Records and Case Preparation

Available records may include pathology and immunophenotyping reports, bone marrow or biopsy findings, molecular or cytogenetic results where relevant, imaging, prior treatment regimens and responses, transplant history, recent laboratory results, infection information, medication lists and specialist summaries. The hospital may request other documents or repeat tests.

MedTransplant can organize the records submitted by the patient or authorized representative, identify obvious gaps and prepare a clearer file for preliminary review and hospital communication.

The MedTransplant Pathway

• The patient or authorized representative submits available medical records.
• MedTransplant organizes the initial medical file and supports a preliminary case-review or Initial Medical Second Opinion pathway where appropriate.
• Potential hospitals or centers are considered in light of clinical needs, expertise, geography, expected cost and patient circumstances.
• The selected specialist team evaluates the case and may propose further investigation, a treatment pathway and a hospital quotation.
• MedTransplant helps clarify the proposal and advocates for transparent, appropriate hospital pricing where applicable, without promising a discount.
• The team coordinates appointments, travel planning and hospital communication when a pathway proceeds.
• Coordination continues through the treatment period, discharge, return planning and post-treatment communication.

Treatment Costs

There is no responsible universal price for CAR T-cell therapy. Costs can depend on the cellular product and manufacturing pathway, diagnostic and eligibility assessment, laboratory work, possible disease-control treatment, conditioning therapy, hospitalization, monitoring, supportive medicines, complications and individual clinical requirements.

After appropriate case review, MedTransplant can request a proposed treatment plan and written hospital quotation, help clarify inclusions and exclusions, and raise questions about unclear or potentially unnecessary costs. A quotation may change if the clinical plan changes, and no discount or saving can be guaranteed.

Why Use MedTransplant Instead of Contacting the Hospital Directly?

Patients are free to contact hospitals directly. MedTransplant provides a structured route for medical-file preparation, program comparison, evaluation coordination, cost clarification and advocacy, travel planning and treatment-period support.

Patients do not pay MedTransplant a referral commission for the standard patient-coordination services described here. Treatment payments are made directly to the treating hospital through its authorized payment channels, and MedTransplant does not add a hidden patient service fee to the hospital quotation.

MedTransplant may maintain contractual or referral relationships with participating healthcare institutions. Those relationships do not transfer clinical decision-making to MedTransplant and must not be presented as increasing the patient’s hospital treatment bill.

Travel and Treatment Coordination

When a hospital pathway proceeds, coordination may include itinerary guidance, appointment planning, communication with the international-patient department, interpreter arrangements, airport or hospital logistics, and ground or air medical transport coordination when clinically and operationally required.

Support may continue during treatment, discharge and return-travel planning, followed by communication and follow-up coordination after the patient returns home. Flights, accommodation, interpreters, transport, medical care and other third-party services are not described as free and may carry separate costs.

Safety and Eligibility

CAR T-cell therapy can cause serious complications, including cytokine release syndrome, neurological toxicity, infections and prolonged low blood counts. Other short- or long-term risks may also apply. Treatment requires specialist assessment, an appropriate monitoring environment and a clear emergency-response and follow-up plan.

Continue exploring

Related MedTransplant guides

Hospital selection

How to Choose a Transplant Hospital Abroad: 10 Questions Patients Should Ask

Questions about clinical expertise, eligibility, safety, costs and follow-up before selecting an international treatment program.

Read guide →

Transplant eligibility

Organ Transplant Eligibility: What Transplant Centers Evaluate Before Accepting a Patient

Understand why diagnosis alone does not establish treatment eligibility and what specialist programs may review.

Read guide →